Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. (2019)

First Author: Catt H
Attributed to:  North West HTMR funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier:

PubMed Identifier: 31372948

Publication URI:

Type: Journal Article/Review

Volume: 37

Parent Publication: PharmacoEconomics

Issue: 12

ISSN: 1170-7690